News
NTRA
41.25
+0.32%
0.13
Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located ...
PR Newswire · 11/23 13:33
Biotech companies Natera and Synthego are laying off a total of 163 employees
A pair of biotechnology companies with offices on the Peninsula are cutting a combined 163 employees. Natera Inc. alerted state employment officials of its layoffs Nov. 4, the same day it notified 58 of its San Carlos-based workers that they were losing t...
American City Business Journals · 11/22 23:14
New Study Further Demonstrates The Ability Of Natera's mPCR Technology To Monitor Immunotherapy Response In Metastatic Uveal Melanoma Patients
Benzinga · 11/21 13:35
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Benzinga · 11/17 10:07
Why Target Shares Are Trading Lower By 14%? Here Are 56 Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 11/16 19:02
Sector Update: Health Care Stocks Back Near Even
Sector Update: Health Care Stocks Back Near Even
MT Newswires · 11/16 16:09
Lowe's, Alcon And Some Other Big Stocks Moving Higher On Wednesday
Benzinga · 11/16 15:57
Sector Update: Health Care Stocks Narrowly Higher
Sector Update: Health Care Stocks Narrowly Higher
MT Newswires · 11/16 14:11
Natera Priced Follow-On Offering of ~11.4M Shares at $35/Share
Benzinga · 11/16 10:25
Natera prices follow-on offering at $35.00/share
Seekingalpha · 11/16 08:31
BRIEF-Natera Says Public Offering Of 11.43 Mln Shares At $35/Share
Reuters · 11/16 04:04
Natera Announces Pricing of Follow-On Offering
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is...
PR Newswire · 11/16 04:01
Natera Prices Common Stock Offering at $35 Per Share
Natera Prices Common Stock Offering at $35 Per Share
MT Newswires · 11/16 03:47
Natera Launches Proposed Follow-On Offering
Natera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-d...
PR Newswire · 11/15 21:30
Natera Files For Common Stock Offering Of Up To $350M
Benzinga · 11/15 21:19
Credit Suisse Maintains Outperform on Natera, Lowers Price Target to $55
Benzinga · 11/14 12:28
--Credit Suisse Adjusts Natera's Price Target to $55 From $70, Keeps Outperform Rating
--Credit Suisse Adjusts Natera's Price Target to $55 From $70, Keeps Outperform Rating
MT Newswires · 11/14 11:09
Robinhood, MicroStrategy And Other Big Losers From Wednesday
Benzinga · 11/10 06:55
Natera reaches four-month low despite Q3 beat
Seekingalpha · 11/09 18:15
BRIEF-Natera Reports Third Quarter 2022 Financial Results
Reuters · 11/08 23:30
More
Webull provides a variety of real-time NTRA stock news. You can receive the latest news about Natera Inc through multiple platforms. This information may help you make smarter investment decisions.
About NTRA
Natera, Inc. is a diagnostics company that is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. The Company’s cell-free deoxyribonucleic acid (DNA) or (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Pre-implantation Genetics (Spectrum), Anora Miscarriage Test (Anora), Non-Invasive Paternity Testing (PAT) and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology.